Research ExplorerPublicationsNephroprotection by theophylline in patients with cisplatin ...

Nephroprotection by theophylline in patients with cisplatin chemotherapy

Standard

Nephroprotection by theophylline in patients with cisplatin chemotherapy : a randomized, single-blinded, placebo-controlled trial. / Benoehr, Peter; Krueth, Patricia; Bokemeyer, Carsten; Grenz, Almut; Osswald, Hartmut; Hartmann, Jorg T.

In: J AM SOC NEPHROL, Vol. 16, No. 2, 02.2005, p. 452-8.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Benoehr, P, Krueth, P, Bokemeyer, C, Grenz, A, Osswald, H & Hartmann, JT 2005, 'Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial', J AM SOC NEPHROL, vol. 16, no. 2, pp. 452-8. https://doi.org/10.1681/ASN.2004030225

APA

Benoehr, P., Krueth, P., Bokemeyer, C., Grenz, A., Osswald, H., & Hartmann, J. T. (2005). Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J AM SOC NEPHROL, 16(2), 452-8. https://doi.org/10.1681/ASN.2004030225

Vancouver

Benoehr P, Krueth P, Bokemeyer C, Grenz A, Osswald H, Hartmann JT. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J AM SOC NEPHROL. 2005 Feb;16(2):452-8. https://doi.org/10.1681/ASN.2004030225

Bibtex

@article{84af6079870c4f1b8614c6bc0d098c23,
title = "Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial",
abstract = "The aim of the present study was to assess the possible prevention of cisplatin-induced impairment of GFR by theophylline in patients with various malignancies. The trial design was parallel, randomized, single blinded, and placebo controlled. Patients received cisplatin at a dosage of 50 mg/m(2) either combined with etoposide, ifosfamide, and epirubicin or with paclitaxel and 5-fluorouracil/folinic acid with the usual precautions, including a standard hydration scheme before application of cisplatin in both arms. In the control arm, placebo was administered; in the verum arm, patients received theophylline in a loading dose of 4 mg/kg intravenously over 30 min before cisplatin, followed by 0.4 mg/kg per min over a minimum of 6 h, and then 350 mg three times daily orally for 4 consecutive days after completion of chemotherapy. GFR of each patient was assessed by renal clearance of inulin within 3 d before and at day 5 after cisplatin chemotherapy. Despite usual precautions, patients in the placebo group had a 21% decrease (range, 11 to 31%) of inulin clearance after a single cycle of cisplatin-containing chemotherapy (92.9 +/- 3.4 versus 71.8 +/- 3.5 ml/min; P < 0.01). Patients who received theophylline had no deterioration of GFR (91.5 +/- 3.7 versus 90.0 +/- 3.8 ml/min; P > 0.05). No adverse effects have been observed during theophylline application. Conventional precautions such as hydration and osmotic diuresis cannot prevent a significant decrease of GFR after a single cycle of cisplatin-containing chemotherapy. The prophylactic application of theophylline as an intravenous loading dose and oral maintenance regimen may preserve kidney function in terms of GFR.",
keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Infusions, Intravenous, Kidney Diseases, Male, Middle Aged, Neoplasms, Primary Prevention, Probability, Prospective Studies, Reference Values, Risk Assessment, Single-Blind Method, Theophylline, Treatment Outcome",
author = "Peter Benoehr and Patricia Krueth and Carsten Bokemeyer and Almut Grenz and Hartmut Osswald and Hartmann, {Jorg T}",
year = "2005",
month = feb,
doi = "10.1681/ASN.2004030225",
language = "English",
volume = "16",
pages = "452--8",
journal = "J AM SOC NEPHROL",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "2",

}

RIS

TY - JOUR

T1 - Nephroprotection by theophylline in patients with cisplatin chemotherapy

T2 - a randomized, single-blinded, placebo-controlled trial

AU - Benoehr, Peter

AU - Krueth, Patricia

AU - Bokemeyer, Carsten

AU - Grenz, Almut

AU - Osswald, Hartmut

AU - Hartmann, Jorg T

PY - 2005/2

Y1 - 2005/2

N2 - The aim of the present study was to assess the possible prevention of cisplatin-induced impairment of GFR by theophylline in patients with various malignancies. The trial design was parallel, randomized, single blinded, and placebo controlled. Patients received cisplatin at a dosage of 50 mg/m(2) either combined with etoposide, ifosfamide, and epirubicin or with paclitaxel and 5-fluorouracil/folinic acid with the usual precautions, including a standard hydration scheme before application of cisplatin in both arms. In the control arm, placebo was administered; in the verum arm, patients received theophylline in a loading dose of 4 mg/kg intravenously over 30 min before cisplatin, followed by 0.4 mg/kg per min over a minimum of 6 h, and then 350 mg three times daily orally for 4 consecutive days after completion of chemotherapy. GFR of each patient was assessed by renal clearance of inulin within 3 d before and at day 5 after cisplatin chemotherapy. Despite usual precautions, patients in the placebo group had a 21% decrease (range, 11 to 31%) of inulin clearance after a single cycle of cisplatin-containing chemotherapy (92.9 +/- 3.4 versus 71.8 +/- 3.5 ml/min; P < 0.01). Patients who received theophylline had no deterioration of GFR (91.5 +/- 3.7 versus 90.0 +/- 3.8 ml/min; P > 0.05). No adverse effects have been observed during theophylline application. Conventional precautions such as hydration and osmotic diuresis cannot prevent a significant decrease of GFR after a single cycle of cisplatin-containing chemotherapy. The prophylactic application of theophylline as an intravenous loading dose and oral maintenance regimen may preserve kidney function in terms of GFR.

AB - The aim of the present study was to assess the possible prevention of cisplatin-induced impairment of GFR by theophylline in patients with various malignancies. The trial design was parallel, randomized, single blinded, and placebo controlled. Patients received cisplatin at a dosage of 50 mg/m(2) either combined with etoposide, ifosfamide, and epirubicin or with paclitaxel and 5-fluorouracil/folinic acid with the usual precautions, including a standard hydration scheme before application of cisplatin in both arms. In the control arm, placebo was administered; in the verum arm, patients received theophylline in a loading dose of 4 mg/kg intravenously over 30 min before cisplatin, followed by 0.4 mg/kg per min over a minimum of 6 h, and then 350 mg three times daily orally for 4 consecutive days after completion of chemotherapy. GFR of each patient was assessed by renal clearance of inulin within 3 d before and at day 5 after cisplatin chemotherapy. Despite usual precautions, patients in the placebo group had a 21% decrease (range, 11 to 31%) of inulin clearance after a single cycle of cisplatin-containing chemotherapy (92.9 +/- 3.4 versus 71.8 +/- 3.5 ml/min; P < 0.01). Patients who received theophylline had no deterioration of GFR (91.5 +/- 3.7 versus 90.0 +/- 3.8 ml/min; P > 0.05). No adverse effects have been observed during theophylline application. Conventional precautions such as hydration and osmotic diuresis cannot prevent a significant decrease of GFR after a single cycle of cisplatin-containing chemotherapy. The prophylactic application of theophylline as an intravenous loading dose and oral maintenance regimen may preserve kidney function in terms of GFR.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Cisplatin

KW - Dose-Response Relationship, Drug

KW - Drug Administration Schedule

KW - Female

KW - Follow-Up Studies

KW - Glomerular Filtration Rate

KW - Humans

KW - Infusions, Intravenous

KW - Kidney Diseases

KW - Male

KW - Middle Aged

KW - Neoplasms

KW - Primary Prevention

KW - Probability

KW - Prospective Studies

KW - Reference Values

KW - Risk Assessment

KW - Single-Blind Method

KW - Theophylline

KW - Treatment Outcome

U2 - 10.1681/ASN.2004030225

DO - 10.1681/ASN.2004030225

M3 - SCORING: Journal article

C2 - 15590762

VL - 16

SP - 452

EP - 458

JO - J AM SOC NEPHROL

JF - J AM SOC NEPHROL

SN - 1046-6673

IS - 2

ER -